Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12C

被引：1

作者：

Griesinger, F. ^{[1
]}

Eberhardt, W. E. E. ^{[2
]}

Hoffknecht, P. ^{[3
]}

Metzenmacher, M. ^{[4
]}

Wehler, T. ^{[5
]}

Kokowski, K. ^{[6
]}

Alt, J. ^{[7
]}

Schuette, W. ^{[8
]}

Jaenicke, M. ^{[9
]}

Fleitz, A. ^{[9
]}

Zacharias, S. ^{[10
]}

Hipper, A. ^{[11
]}

Buller, M. ^{[12
]}

Weichert, W. ^{[13
]}

Groschek, M. ^{[14
]}

von der Heyde, E. ^{[15
]}

Rauh, J. ^{[16
]}

Dechow, T. ^{[17
]}

Sebastian, M. ^{[18
]}

Thomas, M. ^{[19
]}

机构：

[1] Carl von Ossietzky Univ Oldenburg, Pius Hosp, Hematol & Oncol, Oldenburg, Germany

[2] Univ Hosp Essen, Westdeutsch Tumorzentrum, Dept Med Oncol, Essen, Germany

[3] Franziskus Hosp Harderberg, Klin Thoraxonkol, Georgsmarienhutte, Germany

[4] Univ Klinikum Essen, Thorakale Onkol, Essen, Germany

[5] Lungenklin Hemer, Pneumol & Thorakale Onkol, Hemer, Germany

[6] Klinikum Bogenhausen, Klin Pneumol & Pneumol Onkol, Munich, Germany

[7] Univ Med Mainz, Dept Internal Med 3, Mainz, Germany

[8] Hosp Martha Maria Halle Doelau, Innere Med 2, Halle, Germany

[9] IOMEDICO AG, Clin Epidemiol & Hlth Econom, Freiburg, Germany

[10] IOMEDICO AG, Stat, Freiburg, Germany

[11] AIO Studien gGmbH, Project Management, Berlin, Germany

[12] AIO Studien gGmbH, Project Management, Berlin, Germany

[13] Tech Univ Munich, Inst Pathol, Inst Pathol, Munich, Germany

[14] Hamatol Onkol Stolberg, Onkol, Stolberg, Germany

[15] Gemeinschaftspraxis Strahlentherapie & Radioonkol, Onkol Schwerpunktpraxis, Hannover, Germany

[16] Praxis Innere Med, Innere Med, Witten, Germany

[17] Studienzentrum Onkol Ravensburg, Hamatol Onkol, Ravensburg, Germany

[18] Univ Hosp Frankfurt, Hamatol Onkol, Frankfurt, Germany

[19] Thoraxklin Heidelberg, Innere Med & Onkol, Heidelberg, Germany

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.1678

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1364P

引用

页码：S872 / S872

页数：1

共 50 条

[31] Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting
Julian, Cristina
Pal, Navdeep
Gershon, Anda
Evangelista, Marie
Purkey, Hans
Lambert, Peter
Shi, Zhen
Zhang, Qing
BMC CANCER, 2023, 23 (01)
[32] Phase I/II study of D3S-001, a second generation KRAS G12C inhibitor in advanced/metastatic solid tumors with KRAS G12C mutations
Cho, B. C.
Lu, S.
Lee, M. A.
Song, Z.
Park, J. J. W.
Lim, S. M.
Li, Z.
Zhao, J.
Richardson, G.
Zhang, Y.
Zhang, J.
Liu, A.
Chen, C.
Wang, J.
Chen, J.
Wang, A.
Zhang, J.
Chen, Z. G.
Mok, T. S. K.
Johnson, M. L.
ANNALS OF ONCOLOGY, 2024, 35 : S493 - S493
[33] Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting
Cristina Julian
Navdeep Pal
Anda Gershon
Marie Evangelista
Hans Purkey
Peter Lambert
Zhen Shi
Qing Zhang
BMC Cancer, 23
[34] Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer
Cui, Wanyuan
Franchini, Fanny
Alexander, Marliese
Officer, Ann
Wong, Hui-Li
IJzerman, Maarten
Desai, Jayesh
Solomon, Benjamin J.
LUNG CANCER, 2020, 146 : 310 - 317
[35] Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition
Tereza Vaclova
Atanu Chakraborty
James Sherwood
Sarah Ross
Danielle Carroll
J. Carl Barrett
Julian Downward
Elza C. de Bruin
Scientific Reports, 12
[36] Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition
Vaclova, Tereza
Chakraborty, Atanu
Sherwood, James
Ross, Sarah
Carroll, Danielle
Barrett, J. Carl
Downward, Julian
de Bruin, Elza C.
SCIENTIFIC REPORTS, 2022, 12 (01)
[37] Clinicopathological characteristics and treatment patterns observed in real-world care in patients with advanced non-small cell lung cancer (NSCLC) and KRAS G12C mutations in the Flatiron Health (FH)-Foundation Medicine (FMI) Clinico-Genomic Database (CGDB)
Aggarwal, S.
Whipple, S.
Hsu, H.
Tu, H.
Carrigan, G.
Wang, X.
Ngarmchamnanrith, G.
Chia, V.
ANNALS OF ONCOLOGY, 2020, 31 : S860 - S860
[38] Impact of baseline clinicopathologic and genomic features on outcomes to KRAS G12C inhibitors in patients with NSCLC
Lamberti, G.
Cooper, A. J.
Ricciuti, B.
Alessi, J. V.
Barrichello, A. P. de Castro
Pecci, F.
Vaz, V. R.
Nishino, M.
Sholl, L. M.
Heist, R.
Awad, M.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1039 - S1039
[39] Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib"
Jiang, Yanfang
Zhang, Lei
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (09) : e43 - e43
[40] Impact of Baseline Clinicopathologic and Genomic Features on Outcomes to KRAS G12C Inhibitors in Patients with NSCLC
Lamberti, G.
Ricciuti, B.
Alessi, J. V.
Barrichello, A. P. C.
Pecci, F.
Vaz, V. R.
Sholl, L. M.
Awad, M. M.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S49 - S49

← 1 2 3 4 5 →